ONCOTECH

ONCOTECH ONCOTECH ONCOTECH

ONCOTECH

ONCOTECH ONCOTECH ONCOTECH

Oncotech develops mobile Cancer and diabetes detection technologies

Oncotech develops mobile Cancer and diabetes detection technologies Oncotech develops mobile Cancer and diabetes detection technologies Oncotech develops mobile Cancer and diabetes detection technologies

Oncotech develops mobile Cancer and diabetes detection technologies

Oncotech develops mobile Cancer and diabetes detection technologies Oncotech develops mobile Cancer and diabetes detection technologies Oncotech develops mobile Cancer and diabetes detection technologies

Experts in Cancer screening and treatments

International in scope

  • ONCOTECH works with internationally acclaimed oncologists and clinical researchers based in: Japan, Denmark and Russia (Ufa and St Petersburg).           

Therapeutic R&D and focus

  • Diagnostics : mobile in-time cancer screening and treatment technologies targeting: breast,uterus,lung, prostate, pancreas,liver and neuroblastoma                            

R&D partners

  •  Dana Genetics A/S , Eldon Biologicals A/S , Cencor   Technology, LymTreat LLC, PeritonTreat LLC  and  Skolkovo Foundation        

Licensing / Partnership

The most advanced of these first-in-class technologies

Ophtascan™

PeritronTreat™

PeritronTreat™

  • Mobile in-real time cancer  screening diagnostic technology targeting breast, lung,uterus, liver and prostate.                                                      

PeritronTreat™

PeritronTreat™

PeritronTreat™

  • DHMEQ :  proven anticancer  composition by IP administration. Mode of action is in the Peritoneal cavity                                                           


LymTreat ™

PeritronTreat™

CarcinoTreat™

  •  Immunotherapy of breast cancer
    based on neolymphogenesis        


CarcinoTreat™

CarcinoTreat™

CarcinoTreat™

  • anti-carcinomatosis drug treatment by demineralization of the peritoneum

                                              


BiohemTreat ™

CarcinoTreat™

BiohemTreat ™

  •  Biologicals for prevention of surgical Hemostasis                 


Ophtascan™ - mobile Cancer screening

Clinically tested and validated

Ophtascan™ is a mobile in real time cancer screening AI driven technology, clinically tested, validated and ready to be launched with a proper corporate partner. Close to 1000 patients have been tested.  

Cancer screening focus

Ophtascan™ targets all four stages of cancer in: lungs, liver, uterus, prostate and breast

Mobile application ready

Ophtascan™ gives diagnose feedback within 25 sec, with a precision hit-rate over 96%. The mobile application is ready to be integrated .

Diabetes R&D

Ophtascan™ is currently being used to screen Diabetes type 2 , where over 100 patient study is completed with a sold success. The precision hit rate is increasing with every patient and the AI application will be ready to launch in q2 2021. 

Contact Us

Send Message

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Please send us a message  : ar@oncotechservices.com

or call us  : tel  + 46 761 333 396

ONCOTECH LTD

36 Spital Square, London City , E1 6DU, United Kingdom

ONCOTECH NORDIC AB Vastra Ljungbyvagen 275 26651 Vejbystrand , Sweden

Copyright © 2021 ONCOTECH  LTD - All Rights Reserved.